Characterization of two affinity states of adenosine A2a receptors with a new radioligand, 2-[2-(4-amino-3- [125I]iodophenyl)ethylamino]adenosine

DR Luthin, RA Olsson, RD Thompson, DR Sawmiller and J Linden

Department of Internal Medicine, University of Virginia Health Sciences Center, Charlottesville.

Adenosine analogs substituted in the 2-position with arylamino groups have been found to have high affinity and selectivity for A2a adenosine receptors. Two such compounds, 2-[2-(4-aminophenyl)ethylamino]adenosine and 2-[2-4-amino-3-iodophenyl)ethylamino]adenosine (I-APE), were synthesized and found to be potent coronary vasodilators (ED50 < 3 nm). These compounds bind weakly to A1 adenosine receptors of rat cortex (Ki > 150 nM). 125I-APE was synthesized and the new radioligand was found to bind to two affinity states of rat striatal A2a adenosine receptors (Kd = 1.3 +/- 0.1 nM and 19 +/- 4.5 nM). The high affinity site represents a previously unrecognized small (15-20%) fraction of A2a adenosine receptors coupled to G proteins. Guanosine 5'-O-(3- thio)triphosphate (GTP gamma S) reduces specific binding of 125I-APE half-maximally at a concentration of 45 +/- 2 nM. [3H]CGS21680 also binds to two affinity states of A2a receptors on striatal membranes (Kd = 3.9 +/- 0.9 and 51 +/- 5.5 nM), although in previous studies single Kd values ranging from 5 to 15 nM have been reported. This high affinity site is substantiated by the finding that the IC50 of CGS21680 in competition with 125I-APE binding to striatal membranes is shifted leftward in membranes diluted for 4 min before filtration, to selectively dissociate radioligand from low affinity receptors. Assuming that agonist radioligands bind to both coupled and uncoupled forms of striatal A2a adenosine receptors, we could simulate with the computer the finding that the decrease in specific binding induced by GTP gamma S (100 microM) is variable and depends on radioligand concentration, ranging from 20 to 90%. Unlike 125I-APE, [3H]CGS21680 is charged at physiological pH, and treatment of membranes with the pore- forming antibiotic alamethicin uncovers cryptic [3H]CGS21680 but not 125I-APE binding sites. We conclude that the GTP gamma S-sensitive high affinity form of the A2a adenosine receptor can be preferentially labeled by 125I-APE, due to both its high specific activity and its physicochemical properties. Possible functional manifestations of poor coupling of A2a adenosine receptors to G proteins are discussed.

Volume 47, Issue 2, pp. 307-313, 02/01/1995
Copyright © 1995 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				J. J. Kobie, P. R. Shah, L. Yang, J. A. Rebhahn, D. J. Fowell, and T. R. Mosmann T Regulatory and Primed Uncommitted CD4 T Cells Express CD73, Which Suppresses Effector CD4 T Cells by Converting 5'-Adenosine Monophosphate to Adenosine J. Immunol., November 15, 2006; 177(10): 6780 - 6786. [Abstract] [Full Text] [PDF]

				L. J. Murphree, M. A. Marshall, J. M. Rieger, T. L. MacDonald, and J. Linden Human A2A Adenosine Receptors: High-Affinity Agonist Binding to Receptor-G Protein Complexes Containing Gbeta 4 Mol. Pharmacol., February 1, 2002; 61(2): 455 - 462. [Abstract] [Full Text] [PDF]

				D. K. Glover, M. Ruiz, K. Takehana, F. D. Petruzella, L. M. Riou, J. M. Rieger, T. L. Macdonald, D. D. Watson, J. Linden, and G. A. Beller Pharmacological Stress Myocardial Perfusion Imaging With the Potent and Selective A2A Adenosine Receptor Agonists ATL193 and ATL146e Administered by Either Intravenous Infusion or Bolus Injection Circulation, September 4, 2001; 104(10): 1181 - 1187. [Abstract] [Full Text] [PDF]

				S. M. Peirce, T. C. Skalak, J. M. Rieger, T. L. Macdonald, and J. Linden Selective A2A adenosine receptor activation reduces skin pressure ulcer formation and inflammation Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H67 - H74. [Abstract] [Full Text] [PDF]

				M. R. Mazzoni, S. Taddei, L. Giusti, P. Rovero, C. Galoppini, A. D'Ursi, S. Albrizio, A. Triolo, E. Novellino, G. Greco, et al. A Galpha s Carboxyl-Terminal Peptide Prevents Gs Activation by the A2A Adenosine Receptor Mol. Pharmacol., July 1, 2000; 58(1): 226 - 236. [Abstract] [Full Text]

				M. D. Okusa, J. Linden, T. Macdonald, and L. Huang Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney Am J Physiol Renal Physiol, September 1, 1999; 277(3): F404 - F412. [Abstract] [Full Text] [PDF]

				G. P. Matherne, J. Linden, A. M. Byford, N. S. Gauthier, and J. P. Headrick Transgenic A1 adenosine receptor overexpression increases myocardial resistance to ischemia PNAS, June 10, 1997; 94(12): 6541 - 6546. [Abstract] [Full Text] [PDF]

				L. Belardinelli, J. C. Shryock, J. Ruble, A. Monopoli, S. Dionisotti, E. Ongini, D. M. Dennis, and S. P. Baker Binding of the Novel Nonxanthine A2A Adenosine Receptor Antagonist [3H]SCH58261 to Coronary Artery Membranes Circ. Res., December 1, 1996; 79(6): 1153 - 1160. [Abstract] [Full Text]

				T. Mizumura, J. A. Auchampach, J. Linden, R. F. Bruns, and G. J. Gross PD 81,723, an Allosteric Enhancer of the A1 Adenosine Receptor, Lowers the Threshold for Ischemic Preconditioning in Dogs Circ. Res., September 1, 1996; 79(3): 415 - 423. [Abstract] [Full Text]

				E. L. Kilpatrick, P. Narayan, R. M. Mentzer Jr., and R. D. Lasley Cardiac myocyte adenosine A2a receptor activation fails to alter cAMP or contractility: role of receptor localization Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H1035 - H1040. [Abstract] [Full Text] [PDF]